{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T22:22:43Z","timestamp":1768083763642,"version":"3.49.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Idiopathic Multicentric Castleman disease (iMCD) is a type of the rare lymphoproliferative diseases. C-reactive protein (CRP) is a well-recognized biomarker of inflammation, frequently exhibits elevated levels in individuals diagnosed with iMCD. However, its prognostic value of this factor in iMCD remains uncertain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The clinical manifestations, biochemical information, treatment plan and overall survival time (OS) of 68 iMCD patients with basic information such as age, sex, time of first diagnosis, blood routine and serum CRP level data from 6 medical institutionsin China and abroad were retrospectively analyzed. The median follow-up time of the study was 44.47 months. The serum CRP level was divided into two groups according to the prognostic relationship by X-tile software, and then it was included in the risk model CRP-A for predicting death, together with the age of first visit &amp;gt;\u202f60\u202fyears old, Hemoglobin (HGB) \u2264\u202f80g\/L, hepatomegaly and\/or splenomegaly and plasma cell (PC) type. The predictive ability of the clinical model was evaluated by drawing calibration curve and ROC curve. The factors affecting the level of serum CRP were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Using the Kaplan-Meier method, our analysis suggested that a higher serum CRP level (&amp;gt;26.8\u202fmg\/L) was associated with worse overall survival in patients (<jats:italic>p<\/jats:italic>\u202f=\u202f0.004). We developed a multivariable prognostic model based on serum CRP levels to assess survival outcomes in iMCD. The discriminative performance of the model for mortality events was validated through calibration plots and receiver operating characteristic (ROC) curves highlighting CRP as a key biomarker associated with disease prognosis. Additionally, analyzing by chi-square test and Fisher\u2019s exact test showed that age, B-symptoms, hypoalbuminemia, ECOG and plasma cell type were significantly associated with high serum CRP level in patients with iMCD, and that fibrinogen levels was positively correlated with CRP level.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>High serum CRP levels are associated with a variety of clinical manifestations and laboratory abnormalities.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1544250","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:25:45Z","timestamp":1744781145000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic value of serum C-reactive protein in idiopathic multicentric Castleman disease and construction of a prognostic model for patients"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhixiang","family":"Lei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiantian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenting","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cancan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingqing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41572-021-00317-7","article-title":"Castleman disease","volume":"7","author":"Carbone","year":"2021","journal-title":"Nat Rev Dis Prim"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1182\/blood.V124.21.2970.2970","article-title":"Normal circulating B cells are markedly reduced in follicular lymphoma and diffuse large B cell lymphoma at diagnosis","volume":"124","author":"Geuna","year":"2014","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"4859","DOI":"10.21037\/jtd.2019.10.73","article-title":"Clinicopathological comparison and therapeutic approach to Castleman disease\u2014a case-based review","volume":"11","author":"Wojty\u015b","year":"2019","journal-title":"J Thorac Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/ajh.23291","article-title":"The clinical spectrum of Castleman's disease","volume":"87","author":"Dispenzieri","year":"2012","journal-title":"Am J Hematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8\u2013negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1023\/A:1008381006612","article-title":"The oncogenic 30 and 69 bp deletion variants of the EBV LMP-1 gene are common in HIV-negative lymphoproliferations, both malignant and benign","volume":"10","author":"Barozzi","year":"1999","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1182\/blood-2016-11-748855","article-title":"Clinical and pathological characteristics of HIV-and HHV-8\u2013negative Castleman disease","volume":"129","author":"Yu","year":"2017","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/cas.13439","article-title":"Clinical characteristics and outcomes of Castleman disease: a multicenter study of 185 Chinese patients","volume":"109","author":"Zhang","year":"2018","journal-title":"Cancer Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1111\/jcmm.17251","article-title":"Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO","volume":"26","author":"Phillips","year":"2022","journal-title":"J Cell Mol Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/ejh.13702","article-title":"Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease","volume":"107","author":"Goodman","year":"2021","journal-title":"Eur J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"van Rhee","year":"2018","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.6004\/jnccn.2019.5037","article-title":"Diagnosis and Management of Castleman Disease","volume":"17","author":"Abramson","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease","volume":"91","author":"Iwaki","year":"2016","journal-title":"Am J Hematol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e924783","DOI":"10.12659\/MSM.924783","article-title":"Analysis of clinical characteristics, pathological changes and changes of Interleukin-6 (IL-6) and C-reactive protein (CRP) in children with Castleman's disease","volume":"26","author":"Hu","year":"2020","journal-title":"Med Sci Monit"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.2169\/internalmedicine.5046-20","article-title":"Interleukin-6-producing intravascular large B-cell lymphoma with lymphadenopathy mimicking the histology of multicentric Castleman disease","volume":"59","author":"Shiroshita","year":"2020","journal-title":"Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood.2019000931","article-title":"Overview of Castleman disease","volume":"135","author":"Dispenzieri","year":"2020","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"889844","DOI":"10.3389\/fonc.2022.889844","article-title":"Prognostic impact of serum CRP level in head and neck squamous cell carcinoma","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1080\/07853890.2022.2070660","article-title":"Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1\/PD-L1 therapy","volume":"54","author":"Minichsdorfer","year":"2022","journal-title":"Ann Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1182\/blood-2006-07-033969","article-title":"STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation","volume":"109","author":"Verga Falzacappa","year":"2007","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/bjh.13378","article-title":"Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single Centre: paraneoplastic pemphigus is an unfavourable prognostic factor","volume":"169","author":"Dong","year":"2015","journal-title":"Br J Haematol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1634\/theoncologist.2019-0986","article-title":"A novel predictive model for idiopathic multicentric Castleman disease: the international Castleman disease consortium study","volume":"25","author":"Yu","year":"2020","journal-title":"Oncologist"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1053\/j.gastro.2006.10.018","article-title":"STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo","volume":"132","author":"Pietrangelo","year":"2007","journal-title":"Gastroenterology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1544250\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:25:46Z","timestamp":1744781146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1544250\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":23,"alternative-id":["10.3389\/fmed.2025.1544250"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1544250","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"article-number":"1544250"}}